Live
Embecta Corp.
Healthcare · Medical - Instruments & Supplies · NASDAQ
66 candles · 3M · retrieved
Estimated fair value
16.77
Range
10.38–24.51
Price vs value
195% below
Model support
Value
195% below fair value
confidence low
Estimate momentum
◆ mixed
Next catalyst
none scheduled
Volatility
extreme
regime
1M forecast
withheld
Value tells you the size of the gap; the other cells tell you what could close it — and when. A cheap stock without a catalyst can stay cheap.
Forecast withheld
stale data
No intelligence items published yet.
Price trades 195% below the fair-value estimate — EMBC screens as materially undervalued. The 2 models disagree widely (dispersion 53.1%) — treat the range, not the midpoint, as the answer. A valuation gap is not a timing signal and currently has zero ranking weight.
Forward earnings lens
3.1x FY2026 P/E
EPS 1.84+13.3%3 analysts
Shown as context, not blended into fair value, while genuine point-in-time forward-multiple history accumulates.
Where estimates sit vs price 5.69
Peer companies' EV/EBITDA: not shown — unavailable.
Not meaningful for this company type: excess returns model (financials), path-to-profitability (scenario), dividend discount model, total payout (dividends + net buybacks), p/ocf vs peer reits (ffo proxy).
Cheap or expensive — depending on the yardstick
Entry threshold
below 13.42(fair value 16.77 − 20%)
price is inside your band
A valuation threshold, not a timing signal — a cheap stock can keep falling. Alerts wire in when the notification substrate lands.
◆ Estimates mixed (revenue +0.3% · EPS +15.2% · targets 0.0% this month)
Company profile at a glance
Bars are scaled to documented anchors (e.g. 35% operating margin = full bar), not ranked against other companies. Each row stands on its own — there is no hidden total score.
Financials at a glance· latest reported year · 7y of statements
Revenue
$1.1B
-0% per year over the period
Operating margin
22.4%
5y average 25.3%
Free cash flow
$182M
16.9% of revenue
Net debt / EBITDA
4.0×
ROE
-14.7%
net income ÷ equity
ROIC
36.6%
after-tax operating profit ÷ capital
Dividends paid
$35M
latest year
Buybacks
$6M
share repurchases, latest year
Where the revenue dollar went · FY2025
What the current price is assuming
No revenue-growth or margin assumption inside the model's sanity bounds justifies today's price of 5.69. Either the market expects something far outside historical experience, or the price has detached from fundamentals.
What the DCF is made of — present value by year (base case)
Which growth × margin combinations justify today's price
| margin ↓ / growth → | -5% | 0% | 5% | 10% | 15% | 20% | 25% | 30% | 35% | 40% |
|---|---|---|---|---|---|---|---|---|---|---|
| 60% | ||||||||||
| 55% |
Price vs fair value through time
— price · — fair value (band = bear–bull). Vintages accumulating since 2026-08-09 (recorded at compute time; no historical backfill).
Fair value if assumptions move — discount rate × terminal growth
| discount rate ↓ | g 0% | g 1% | g 2% | g 3% | g 4% |
|---|---|---|---|---|---|
| 5.9% | 59.38 | 68.33 | 81.86 | 104.73 | 151.72 |
| 6.4% | 53 | 60.1 | 70.43 | 86.83 | 116.93 |
| 6.9% | 47.55 |
Terminal value is 59% of the total. Solid years are consensus-anchored; lighter years fade to the stable rate.
| 50% |
|---|
| 45% |
|---|
| 40% |
|---|
| 35% |
|---|
| 30% |
|---|
| 25% |
|---|
| 20% |
|---|
| 15% |
|---|
| 10% |
|---|
| 5% |
|---|
| 0% |
|---|
Sage cells are the assumption pairs that make the model value equal today's price (±2%) — none inside these bounds — the price asks for more than this grid allows.
| 53.27 |
| 61.33 |
| 73.52 |
| 94.12 |
| 7.4% | 42.85 | 47.51 | 53.91 | 63.21 | 78 |
|---|
| 7.9% | 38.74 | 42.59 | 47.75 | 55.01 | 66 |
|---|
| 8.4% | 35.13 | 38.33 | 42.54 | 48.31 | 56.7 |
|---|
| 8.9% | 31.93 | 34.62 | 38.09 | 42.74 | 49.3 |
|---|
Cells compare each implied fair value with the current price 5.69: green above it, burgundy below. Outlined cell = base case.